Feature | March 18, 2011 | Adhir Shroff, M.D., MPH

Straight From the Wrist...

A review of recent transradial study data

Transradial Approach (Left vs. Right) and Procedural Times During Coronary Procedures: TALENT study
Alessandro Sciahbasi, et al. American Heart Journal, 2011, 161: 172-9

Study design: Prospective, randomized 1,467 patients (Jan. 2009-Dec. 2009) to right radial approach (RRA) or left radial approach (LRA).

Primary endpoint: Fluoroscopy time for diagnostic angiography and percutaneous coronary intervention (PCI) evaluated independently

Results: Diagnostic angiography:
• LRA had lower fluoroscopy time (146 sec. vs. 168 sec.)
• LRA less radiation exposure to patient (dose area product: 10.7 Gy cm2 vs. 12.1 Gy cm2)
PCI:
• No difference in fluoroscopy time between groups
Of note, differences between LRA and RRA were limited to patients ?70 and inexperienced TR operators

Bottom line: • Left radial access is associated with lower fluoroscopy times and radiation exposure to the patient.
• This advantage seems to be evident in inexperienced operators and elderly patients

Randomized Comparison of Transradial Coronary Angiography
Via Right or Left Radial Artery Approaches

Yumiko Kanei, et al. American Journal of Cardiology, 2011, 107: 195-197

Study design: Prospective, randomized 193 patients (6/09-8/09) to either right or left radial approach

Primary endpoint: Procedural difficulty: 1) use of hydrophilic or coronary wire for tortuosity, 2) stiff wire use for engagement, 3) ?3 catheters used for either ostium, 4) inability to selectively engage coronary artery

Results: No difference in procedural difficulty between right and left radial approaches (17 vs. 20%). Fewer catheters were used and lower overall procedure time was noted with the right radial approach.

Bottom line: Procedural success was similar between right and left access sites.

Sheathless Transradial Intervention Using Standard Guide Catheters

Aaron M. From, et al. Catheterization and Cardiovascular Interventions, 2010, 76: 911–916

Study design: • Case series of 10 patients undergoing sheathless transradial percutaneous coronary intervention (TR-PCI)
• Sheathless guides were created using 125 cm long, 5 or 6 French diagnostic catheters serving as a taper for a 7 or 8 French Vista Brite tip guiding catheter (Cordis Corp.)

Primary endpoint: Procedural success, access site complications

Results: • 7 French guiding catheter utilized in 6/10 patients and 8 French system in 4/10 patients
• 14/15 lesions treated successfully
• No access site complications

Bottom line: Sheathless TR-PCI is safe and effective

Comparison of Procedural and Late-Term Outcomes
Revascularization for Unprotected Left Main (UPLM) Coronary Artery Disease: Transradial Versus Transfemoral Method of Percutaneous Coronary

Yue-Jin Yang, et al. Journal of the American College of Cardiology, Cardiovascular Interventions, 2010, 3; 1035-1042

Study design: Prospective cohort series, patients recruited between April 2004 and April 2009 from a single center in Beijing, China

Primary endpoint: Angiographic, procedural success, MACE and bleeding events

Results: 821 patients (353 TR and 468 TF) underwent UPLM PCI with DES. LM bifurcation disease and bifurcation stenting more common in TF approach. Similar angiographic, procedural success and MACE rates. Shorter hospital stays and less TIMI bleeding in TR group (0.6 vs. 2.8%, p=0.02)

Bottom line: LM stenting can be performed safely using the TR approach. Access site should be chosen based on lesion characteristics


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now